Skip to content

AcrySof™ IQ Vivity™ DAT415 (REF DAT415.120)Recalls & reported problems

Alcon Laboratories, Inc. · Sterile UV Absorbing Acrylic Foldable Aspheric Wavefront-Shaping Toric Posterior Chamber Intraocular Lenses · Class 3 · Implant

All models of AcrySof IQ Vivity (225)

Data updated Oct 16, 2026 from official FDA records · Editorial policy

Adverse event reports
2
Deaths reported
0
Injuries reported
2
Recalls naming it
0

Summary

The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 00380652427753), received between Feb 2, 2022 and Feb 27, 2023 — classified as 2 injuries.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.

Most reported problems

Device problems

  • Adverse Event Without Identified Device or Use Problem2

Patient problems

  • Blurred Vision2
  • Visual Disturbances1
  • Visual Impairment1

Recent adverse event reports

The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.

  • InjuryFeb 27, 2023Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem

    A NON-HEALTHCARE PROFESSIONAL REPORTED THAT FOLLOWING AN INTRAOCULAR LENS (IOL) IMPLANT PROCEDURE, THE PATIENT EXPERIENCED BLURRY AND POOR-QUALITY VISION, THE CLINICAL REASON WAS 20/40 BCVA POST OP. THE IOL EXPLANTED AND EXCHANGED IN A SECONDARY PROCEDURE OR ATIOL LENS (LIGHT ADJUSTABLE LENS). ADDITIONAL INFORMATION HAS BEEN REQUESTED AND PATIENT DETAILS, CONCOMITANT PRODUCT, REPLACEMENT DETAILS HAS BEEN RECEIVED.

    Patient problems: Blurred Vision; Visual Impairment

    MAUDE report 16448290 ↗
  • InjuryFeb 2, 2022Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem

    A FACILITY REPRESENTATIVE REPORTED THAT FOLLOWING AN INTRAOCULAR LENS (IOL) IMPLANT PROCEDURE, THE PATIENT EXPERIENCED BLURRED VISION AND REFRACTIVE SURPRISE. THE IOL WAS EXCHANGED FOR ANOTHER LENS MODEL 1 MONTH FOLLOWING THE INITIAL IMPLANT PROCEDURE. ADDITIONAL INFORMATION HAS BEEN REQUESTED.

    Patient problems: Blurred Vision; Visual Disturbances

    MAUDE report 13421231 ↗

Other Extended depth of focus intraocular lens devices

All Extended depth of focus intraocular lens devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page